Takeda’s April-December Sales Up 4.6%, but Flat at CER

Takeda Pharmaceutical logged a sales rise of 4.6% in April-December 2023 as growth of its mainstay products and favorable currency moves helped it counter the loss of exclusivity (LOE) of the ADHD therapy Vyvanse (lisdexamfetamine dimesylate) and other drugs. In...read more